Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S E Parker

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Human Toxicology|July 1, 1989
Use and abuse of volatile substances in industryS E Parker
Methods in Molecular Medicine|February 15, 2011
Systemic delivery of therapeutic proteins by intramuscular injection of plasmid DNAH M Horton, S E Parker
Methods in Molecular Medicine|February 15, 2011
Local Delivery of Therapeutic Proteins by Intratumoral Injection of Plasmid DNA-Lipid ComplexesH M Horton, S E Parker
Pharmacoeconomics|January 9, 1992
Pharmacoeconomics of intravenous drug administrationS E Parker, P G Davey
Viral Immunology|January 1, 1990
H-2 restriction and serotype crossreactivity of anti-reovirus cytotoxic T lymphocytes (CTL)S E Parker, D W Sears
Pharmacoeconomics|April 8, 1995
Once-daily aminoglycoside administration in gram-negative sepsis. Economic and practical aspectsS E Parker, P G Davey
The Journal of Antimicrobial Chemotherapy|February 1, 1993
Pharmacoeconomics of antimicrobial prophylaxisP G Davey, S E Parker, M M Malek
Virology|December 1, 1989
Sequence analysis reveals extensive polymorphism and evidence of deletions within the E2 glycoprotein gene of several strains of murine hepatitis virusS E Parker, T M Gallagher, M J Buchmeier
BJOG : an International Journal of Obstetrics and Gynaecology|April 10, 2015
Intrauterine device use and the risk of pre-eclampsia: a case-control studyS E Parker, S S Jick, M M Werler
Current Opinion in Molecular Therapeutics|November 22, 2001
Technology evaluation: interleukin-2 gene therapy for the treatment of renal cell carcinomaR A Figlin, S E Parker, H M Horton
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Human Toxicology|July 1, 1989
Use and abuse of volatile substances in industryS E Parker
Methods in Molecular Medicine|February 15, 2011
Systemic delivery of therapeutic proteins by intramuscular injection of plasmid DNAH M Horton, S E Parker
Methods in Molecular Medicine|February 15, 2011
Local Delivery of Therapeutic Proteins by Intratumoral Injection of Plasmid DNA-Lipid ComplexesH M Horton, S E Parker
Pharmacoeconomics|January 9, 1992
Pharmacoeconomics of intravenous drug administrationS E Parker, P G Davey
Viral Immunology|January 1, 1990
H-2 restriction and serotype crossreactivity of anti-reovirus cytotoxic T lymphocytes (CTL)S E Parker, D W Sears
Pharmacoeconomics|April 8, 1995
Once-daily aminoglycoside administration in gram-negative sepsis. Economic and practical aspectsS E Parker, P G Davey
The Journal of Antimicrobial Chemotherapy|February 1, 1993
Pharmacoeconomics of antimicrobial prophylaxisP G Davey, S E Parker, M M Malek
Virology|December 1, 1989
Sequence analysis reveals extensive polymorphism and evidence of deletions within the E2 glycoprotein gene of several strains of murine hepatitis virusS E Parker, T M Gallagher, M J Buchmeier
BJOG : an International Journal of Obstetrics and Gynaecology|April 10, 2015
Intrauterine device use and the risk of pre-eclampsia: a case-control studyS E Parker, S S Jick, M M Werler
Current Opinion in Molecular Therapeutics|November 22, 2001
Technology evaluation: interleukin-2 gene therapy for the treatment of renal cell carcinomaR A Figlin, S E Parker, H M Horton
Pageof 5